Gwen Huitt, who will lead today's discussion. ARIKAYCE is associated with risk of increased respiratory adverse reactions, including allergic inflammation of lungs, coughing up blood, severe breathing problems, and worsening of COPD. This means FDA has approved this drug for a limited and specific patient population and studies on the drug may have only answered focused questions about its safety and effectiveness. This product was approved by FDA using the limited population pathway. ARIKAYCE is a prescription medicine used to treat adults with refractory, difficult to treat mycobacterium avium complex MAC lung disease, as part of a combination antibacterial drug treatment plan or regimen. Before we begin, I'd like to share some important information you should know about ARIKAYCE. Today's program will focus on the journey to ARIKAYCE, amikacin liposome inhalation suspension, and you'll hear from a leading physician expert and a patient who is taking ARIKAYCE. Thank you for joining us for In The Know, let's talk about ARIKAYCE. Hi everyone, and welcome to today's program.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |